Clinical Trials Logo

Cognitive Dysfunction clinical trials

View clinical trials related to Cognitive Dysfunction.

Filter by:

NCT ID: NCT05260515 Not yet recruiting - Clinical trials for Mild Cognitive Impairment

Protecting Alzheimer Caregivers Using Technology Through Staying Sharp

PROACTS
Start date: April 30, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

PROACTS is a Phase I/II study to assess the efficacy of AARP Staying Sharp online health program, focusing on the health of non-professional home-based caregivers of persons with Alzheimer's disease and related dementias (ADRD). PROACTS has three aims. Aim 1&2 is an one-time survey study to evaluate the current uptake and utilization of Staying Sharp among caregivers. Aim 3 is a single-group intervention to assess how Staying Sharp may maintain health and function for caregivers of persons with ADRD. Participants will participate in a 4-month program with a 4-month follow-up. Aim 1&2: Characterize caregivers of persons with ADRD using Staying Sharp and evaluate user experiences of Staying Sharp. Aim 3: Establish preliminary efficacy of Staying Sharp program.

NCT ID: NCT05258058 Active, not recruiting - Clinical trials for Cognitive Dysfunction

Feasibility of the Memory and Attention Adaptation-Training Geriatrics Intervention in Older Cancer Survivors With Mild Cognitive Impairment

urochester
Start date: December 10, 2021
Phase: N/A
Study type: Interventional

Cancer-related cognitive dysfunction (CRCD) affects up to 75% of patients receiving chemotherapy and older adults are at greater risk of developing CRCD, which can negatively affect their functional independence and quality of life. Memory and Attention Adaptation Training-Geriatrics (MAAT-G) is a cognitive behavioral therapy-based intervention tailored specifically for older adults and the feasibility of MAAT-G in older cancer survivors with Mild Cognitive Impairment (MCI) is being evaluated.

NCT ID: NCT05256745 Recruiting - Clinical trials for Non-metastatic Breast Cancer

RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer

RAGE
Start date: June 6, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a pilot study to evaluate the effects of azeliragon to decrease cardiac toxicity from chemotherapy and the safety of azelirgaon when given with chemotherapy. The Investigators hypothesize that there will be no significant interaction with Azeliragon and chemotherapy and that targeting the RAGE pathway will decrease anthracycline related cardiotoxicity and chemotherapy related cognitive decline.

NCT ID: NCT05256199 Active, not recruiting - Cognitive Decline Clinical Trials

Dutch Multidomain Lifestyle Intervention in Older Adults at Risk of Cognitive Decline

FINGER-NL
Start date: February 24, 2022
Phase: N/A
Study type: Interventional

FINGER-NL is a multi-center, randomized, controlled, multidomain lifestyle intervention trial among 1,206 older adults at risk for cognitive decline with a duration of 24 months. Participants are randomized in a 1:1 ratio to a personalized multi-domain lifestyle intervention (high-intensity intervention group) versus online access to general lifestyle-related health information (low-intensity intervention group).

NCT ID: NCT05253365 Completed - Clinical trials for Mild Cognitive Impairment

French Memory Support System: A Pilot Study

Start date: March 3, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to develop a linguistically and culturally appropriate adaptation of the Memory Support System (MSS), an evidence-based intervention to train persons with mild cognitive impairment (MCI) to complete personal goals and instrumental activities of daily living independently. The study will involve development of the associated manual, training and patient forms, and outcome measures, and pilot testing of the intervention in a group of French-speaking individuals with MCI and their care partners

NCT ID: NCT05251454 Recruiting - Cognitive Deficit Clinical Trials

Studying the Effects of Brain Stimulation on Cognitive Control and Associated EEG in Human Subjects.

Start date: June 20, 2022
Phase: N/A
Study type: Interventional

This is a basic neuroscience study of modulating brain oscillations involved in cognitive control. We will record brain signals and stimulate specific regions of the brain in human participants who are undergoing monitoring for epilepsy surgery. It is not a clinical trial for treating any disease.

NCT ID: NCT05250349 Recruiting - Heart Failure Clinical Trials

TRAnscranial Doppler CErebral Blood Flow and Cognitive IMPAIRment in Heart Failure

TRACE-IMPAIR
Start date: September 1, 2021
Phase:
Study type: Observational

TRACE-IMPAIR is a prospective, clinical study of consecutive patients that evaluates the relationship between heart failure (HF) and cognitive impairment in relation to carotid and cerebral flow. The carotid and cerebral flow will be assessed using Doppler ultrasonography, and cognitive function will be estimated during routine neuropsychological tests. It is an observational, three(natural)-group, single-center study. It is also an Academic Registry - the scientific activity of the Faculty of Medicine, Collegium Medicum, Jagiellonian University, and John Paul II Hospital.

NCT ID: NCT05249504 Not yet recruiting - Depressive Symptoms Clinical Trials

Effectiveness of AMICOPE Intervention to Maintain Self-Perceived Health and Intrinsic Capacity in Older People

EFICIS
Start date: April 1, 2022
Phase: N/A
Study type: Interventional

In their day to day, persons do from simple to more or less complicated tasks and activities (ie: stand from a chair, open a door, shopping, read, drive, play chess, remind an appointment...). Such ability to do things is called capacity. Intrinsic capacity is the combination of all the physical and mental capacities that a person has, and reach its maximum in the early adulthood and then declines as the person ages. Each kind of capacity declines at her own speed (which may be faster or slower according to each person lifestyle), and once drops below a threshold may lead to a reduction in quality of life and loss of autonomy. Nevertheless there are some actions that may be effective to prevent or slow such decline. To do so the investigators have design an intervention that combines several things of different nature (what is know as a complex intervention) called AMICOPE. The AMICOPE intervention is performed in the community or in primary care centers through 12 weekly group sessions of 2 h 30 min which combine structured and adapted physical activity, group dynamics to promote social support and address loneliness, social isolation and depressive symptoms, and dietary advice. Our study is addressed to persons over 70 with light problems in mobility, nutrition or mood state. The purpose of this study is to assess if the AMICOPE intervention is better than the standard advice to follow healthy lifestyles to improve or maintain self-perceived health, mobility, nutritional status an psychological wellbeing.

NCT ID: NCT05245903 Not yet recruiting - Alzheimer Disease Clinical Trials

Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside

Emerald-NRAD
Start date: May 2022
Phase:
Study type: Observational

This project's main goal is to use state-of-the-art passive sensing techniques to identify digital biomarkers that relate to bioenergetic changes in the brain due to nicotinamide riboside supplementation in those with mild cognitive impairment and mild Alzheimer's dementia.

NCT ID: NCT05245253 Recruiting - Critical Illness Clinical Trials

Trauma and Critical Care Exposure Examined With PET (TRAPETS)

TRAPETS
Start date: April 1, 2022
Phase:
Study type: Observational

The overall aim is to examine the impact of trauma and critical illness on the brain, peripheral immune system and cognition. This is a prospective study where a study group exposed to trauma and intensive care will be be examined with consecutive PET imaging, EEG, biomarkers and cognitive testing within 3 weeks of the trauma, after 3 months and finally after 12 months. The study group will consist of twenty trauma patients treated in the intensive care unit.